平田 あや

Medicine & Life Sciences

1. Cardiovascular Diseases 100%
2. Population 96%
3. Chronic Renal Insufficiency 84%
4. Dyslipidemias 74%
5. Cohort Studies 73%
6. Hypertension 71%
7. Japan 67%
8. Confidence Intervals 60%
9. Glomerular Filtration Rate 58%
10. Mortality 55%
11. Cystatin C 53%
12. Coronavirus 48%
13. HDL Cholesterol 47%
14. Diabetes Mellitus 45%
15. Fatty Liver 44%
16. Health Insurance 43%
17. Smoking 35%
18. Cardio Ankle Vascular Index 34%
19. Coronary Vessels 34%
20. Odds Ratio 34%
21. Serum 32%
22. Metabolomics 28%
23. Capillary Electrophoresis 27%
24. Branched Chain Amino Acids 27%
25. lipoprotein cholesterol 26%
26. Pioglitazone 26%
27. alogliptin 26%
28. Natriuretic Peptides 26%
29. Urban Population 25%
30. Tokyo 24%
31. 3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine 24%
32. Kidney 24%
33. ipragliflozin 23%
34. Tobacco Products 23%
35. Intra-Abdominal Fat 23%
36. Fasting 23%
37. Metformin 22%
38. Chronic Hepatitis B 22%
39. Forced Expiratory Volume 22%
40. HDL Lipoproteins 22%
41. Blood Pressure 22%
42. Sleep Initiation and Maintenance Disorders 22%
43. Chronic Hepatitis C 21%
44. Apolipoprotein A-I 21%
45. Uric Acid 21%
46. Cross Infection 21%
47. Canagliflozin 20%
48. Amlodipine 20%
49. Brain Natriuretic Peptide 20%